|Table of Contents|

NCAPD3 Inhibits Apoptosis of Prostate Cancer Cellsby Activating AKT-FOXO Signaling Pathway(PDF)

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

Issue:
2021年03期
Page:
90-95
Research Field:
·生物学·
Publishing date:

Info

Title:
NCAPD3 Inhibits Apoptosis of Prostate Cancer Cellsby Activating AKT-FOXO Signaling Pathway
Author(s):
He Wenzheng; Wu Qingxin; Liu Ping
School of Life Sciences,Nanjing Normal University,Institute of Biochemistry and Biological Products,Nanjing 210023,China
Keywords:
prostate cancer; apoptosis; NCAPD3; AKT; FOXO1/3A
PACS:
R36
DOI:
10.3969/j.issn.1001-4616.2021.03.014
Abstract:
NCAPD3(non SMC condensin II complex subunit D3)is a subunit of condensin II complex. Its main function in cells is to regulate the condensation and stabilization of chromatin during mitosis. NCAPD3 also plays a role in promoting cancer in prostate cancer. This study was to explore the molecular mechanism of NCAPD3 in promoting the development of prostate cancer. Firstly,the expression of NCAPD3 in different cancers was analyzed by using the database,and then the expression of p-AKT and NCAPD3 in normal prostate cells and various prostate cancer cells were detected. Secondly,siRNA was used to knock down NCAPD3 in LNCaP and overexpression of NCAPD3 in DU145. Western blot was used to detect the phosphorylation level of AKT(Thr308 and Ser473),the expression level of FOXO1/3A and downstream apoptosis related factors,and flow cytometry was used to detect the apoptosis of prostate cancer cells. The results showed that NCAPD3 was highly expressed in prostate cancer. NCAPD3 activated AKT through phosphorylation,and then regulated the transcriptional activities of FOXO1 and FOXO3A,inhibited the apoptosis of prostate cancer cells,and was beneficial to the growth of prostate cancer cells,eventually lead to the malignant progression of prostate cancer. This study found that NCAPD3,as a tumor promoting gene in prostate cancer,may become a new target gene for clinical diagnosis and treatment of prostate cancer.

References:

[1] PEREZ C A,FENSOM G K,ANDREWS C,et al. Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank[J]. British journal of cancer,2020,123(12):1808-1817.
[2]MOROVA T,MCNEILL D R,LALLOUS N,et al. Androgen receptor-binding sites are highly mutated in prostate cancer[J]. Nature communications,2020,11(1):832.
[3]COUDERC A L,NICOLAS E,BOISSIER R,et al. Impact of androgen deprivation therapy associated to conformal radiotherapy in the treatment of d’amico intermediate-/high-risk prostate cancer in older patients[J]. Cancers(Basel),2020,13(1):75.
[4]KAKUI Y,UHLMANN F. SMC complexes orchestrate the mitotic chromatin interaction landscape[J]. Current genetics,2018,64(2):335-339.
[5]HIRANO T. Condensin-based chromosome organization from bacteria to vertebrates[J]. Cell,2016,164(5):847-857.
[6]PAUL M R,HOCHWAGEN A,ERCAN S. Condensin action and compaction[J]. Current genetics,2019,65(2):407-415.
[7]ZHANG P,LIU L,HUANG J,et al. Non-SMC condensin I complex,subunit D2 gene polymorphisms are associated with Parkinson’s disease:a Han Chinese study[J]. Genome,2014,57(5):253-257.
[8]YUAN C W,SUN X L,QIAO L C,et al. Non-SMC condensin I complex subunit D2 and non-SMC condensin II complex subunit D3 induces inflammation via the IKK/NF-κB pathway in ulcerative colitis[J]. World journal of gastroenterology,2019,25(47):6813-6822.
[9]MARTIN C A,MURRAY J E,CARROLL P,et al. Mutations in genes encoding condensin complex proteins cause microcephaly through decatenation failure at mitosis[J]. Genes development,2016,30(19):2158-2172.
[10]DAWKINS J B,WANG J,MANIATI E,et al. Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinoma[J]. Cancer research,2016,76(16):4861-4871.
[11]REAGAN S S,AHMAD N. RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells[J]. Cancer research,2006,66(2):1062-1069.
[12]FARHAN M,WANG H,GAUR U,et al. FOXO signaling pathways as therapeutic targets in cancer[J]. International journal of biological sciences,2017,13(7):815-827.
[13]FABRE S,LANG V,BISMUTH G. PI3-kinase and the control of T cell growth and proliferation by FoxOs[J]. Bulletin du cancer,2006,93(5):E36-38.
[14]MARK D M L. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes[J]. Nature genetics,2015,47(2):106-114.
[15]JACQUES L. hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature[J]. The American journal of surgical pathology,2008,32(2):205-209.
[16]CHEN H,ZHOU L,WU X,et al. The PI3K/AKT pathway in the pathogenesis of prostate cancer[J]. Frontiers in bioscience(Landmark Ed),2016,21:1084-1091.
[17]MATSUZAKI H,LEE S,MAEDA M,et al. FoxO1 regulates apoptosis induced by asbestos in the MT-2 human T-cell line[J]. Journal of immunotoxicology,2016,13(5):620-627.
[18]FASANO C,DISCIGLIO V,BERTORA S. FOXO3a from the nucleus to the mitochondria:a round trip in cellular stress response[J]. Cells,2019,8(9):1110.
[19]PORTA C,PAGLINO C,MOSCA A. Targeting PI3K/Akt/mTOR signaling in cancer[J]. Fronties oncology,2014,4:64.
[20]CHEN H,ZHOU L,WU X,et al. The PI3K/AKT pathway in the pathogenesis of prostate cancer[J]. Frontiers in bioscience(Landmark Ed),2016,21:1084-1091.
[21]PUSSILA M,T??EN P,EINARSDOTTIR E,et al. Mlh1 deficiency in normal mouse colon mucosa associates with chromosomally unstable colon cancer[J]. Carcinogenesis,2018,39(6):788-797.
[22]DAWKINS J B,WANG J,MANIATI E,et al. Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinoma[J]. Cancer research,2016,76(16):4861-4871.

Memo

Memo:
-
Last Update: 2021-09-15